Sound waves and a drug team up to attack deadly brain tumors
NCT ID NCT06039709
First seen Apr 30, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This pilot study tests a new approach called sonodynamic therapy for people with recurrent glioblastoma, a type of brain cancer that has come back. The treatment combines an investigational drug (5-ALA) with low-intensity focused ultrasound to target and damage tumor cells before surgery. The study will enroll 11 participants to check if the procedure is safe and feasible, not yet whether it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
5-ALA (a drug that makes tumor cells sensitive to ultrasound) combined with low-intensity focused ultrasound
What this could lead to
If it works, this could point toward a new, non-invasive way to damage glioblastoma cells and improve treatment options for this aggressive brain cancer.
What could go wrong
This is a very early (Phase 1) pilot study with only 11 participants. It focuses on safety, not effectiveness, and the treatment is limited to part of the tumor. Risks include bleeding, brain swelling, and the therapy may not shrink the tumor.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.